Related Experiment Video
Updated: Jul 21, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S Conjeevaram1, Michael W Fried, Lennox J Jeffers
1Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109-0362, USA. omsairam@umich.edu
Gastroenterology
|August 8, 2006
Summary
African Americans (AA) with chronic hepatitis C have lower sustained virologic response (SVR) rates to peginterferon and ribavirin compared to Caucasian Americans (CA). These disparities persist regardless of disease characteristics or treatment adherence.
Area of Science:
- Hepatology
- Virology
- Clinical Trials
Background:
- Chronic hepatitis C treatment response varies significantly by race.
- African Americans (AA) demonstrate lower efficacy with interferon-based therapies compared to Caucasian Americans (CA).
Purpose of the Study:
- To investigate the reasons for differential treatment responses in AA versus CA patients with chronic hepatitis C genotype 1.
- To compare sustained virologic response (SVR) rates between AA and CA patients receiving peginterferon alfa-2a and ribavirin.
Main Methods:
- A multicenter trial treated 196 AA and 205 CA treatment-naive patients with HCV genotype 1.
- Treatment involved peginterferon alfa-2a (180 microg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks.
- Sustained virologic response (SVR) was the primary endpoint, with analyses of baseline characteristics and adverse events.
Main Results:
- SVR rates were significantly lower in AA (28%) compared to CA (52%) (P < .0001).
- Racial differences in viral response emerged early (week 4), with higher breakthrough viremia in AA.
- Despite similar adverse events and dose modifications, CA showed a 1.96-fold higher likelihood of SVR.
Conclusions:
- African Americans with chronic hepatitis C genotype 1 exhibit inferior virologic response rates to peginterferon and ribavirin compared to Caucasian Americans.
- Observed racial disparities in treatment outcomes are not attributable to differences in disease characteristics, viral load, or medication adherence.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...